Amedisys Inc (NASDAQ:AMED) Given Average Recommendation of “Buy” by Brokerages

Amedisys Inc (NASDAQ:AMED) has been assigned an average rating of “Buy” from the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $131.74.

Several research analysts have commented on AMED shares. Raymond James cut shares of RioCan Real Estate Investment Trust to a “hold” rating in a report on Monday. ValuEngine upgraded shares of Zumiez from a “sell” rating to a “hold” rating in a report on Saturday, June 22nd. BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 9th. Jefferies Financial Group set a $150.00 price target on shares of Amedisys and gave the stock a “buy” rating in a report on Monday, July 8th. Finally, Barclays set a €77.00 ($89.53) price target on shares of HeidelbergCement and gave the stock a “buy” rating in a report on Thursday, March 21st.

In other news, Director Jake L. Netterville sold 1,863 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The shares were sold at an average price of $118.17, for a total transaction of $220,150.71. Following the completion of the sale, the director now owns 73,700 shares in the company, valued at approximately $8,709,129. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jeffrey A. Rideout sold 1,263 shares of the business’s stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $114.33, for a total transaction of $144,398.79. Following the sale, the director now owns 5,554 shares of the company’s stock, valued at approximately $634,988.82. The disclosure for this sale can be found here. Insiders have sold a total of 45,028 shares of company stock valued at $5,210,707 in the last 90 days. Insiders own 2.90% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Alpha Quant Advisors LLC raised its position in Amedisys by 137.0% in the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after purchasing an additional 137 shares during the last quarter. Tompkins Financial Corp purchased a new stake in Amedisys in the 2nd quarter valued at $37,000. Captrust Financial Advisors raised its position in Amedisys by 161.8% in the 4th quarter. Captrust Financial Advisors now owns 597 shares of the health services provider’s stock valued at $70,000 after purchasing an additional 369 shares during the last quarter. NEXT Financial Group Inc purchased a new stake in Amedisys in the 2nd quarter valued at $82,000. Finally, Meeder Asset Management Inc. raised its position in Amedisys by 102.3% in the 1st quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock valued at $120,000 after purchasing an additional 488 shares during the last quarter. Hedge funds and other institutional investors own 86.45% of the company’s stock.

NASDAQ AMED traded up $3.51 on Friday, hitting $129.58. 25,440 shares of the stock were exchanged, compared to its average volume of 318,813. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.69. Amedisys has a fifty-two week low of $92.08 and a fifty-two week high of $140.91. The firm has a market cap of $4.04 billion, a P/E ratio of 35.74, a PEG ratio of 1.54 and a beta of 1.34. The firm has a 50-day simple moving average of $119.20.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings results on Tuesday, April 30th. The health services provider reported $1.11 EPS for the quarter, topping the consensus estimate of $0.89 by $0.22. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The company had revenue of $467.34 million during the quarter, compared to analysts’ expectations of $460.83 million. During the same quarter in the previous year, the business posted $0.79 EPS. The firm’s revenue was up 17.0% on a year-over-year basis. Analysts forecast that Amedisys will post 4.08 EPS for the current fiscal year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

See Also: Lock-Up Period Expiration

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.